tional mutation detection fail to identify heterozygous deletions because the normal allele masks the deleted segment. In sequence analysis, apparent loss of heterozygosity of one or more intragenic single nucleotide polymorphisms (SNPs) may be the only sign of a deletion in family studies. Strategies that detect copy number variations, such as Southern blotting, real-time PCR, and fiber FISH, are thus necessary to integrate sequencing. Development of the MLPA (Multiplex Ligation-dependent Probe Amplification) technique to detect complete or partial gene deletions or duplications has greatly improved mutation screening. 8 This technique is an easy and sensitive method based on the simultaneous hybridization and ligation of several probes that matched to single exons in a single reaction tube, followed by PCR and analysis by capillary electrophoresis. If a deletion is present, even on only one exon of a single allele, the corresponding peak is reduced ( Figure 1) ; enhanced peaks suggest duplication.
Here we describe MLPA first application to the RPS19 gene in the molecular diagnosis of DBA.
Routine sequence analysis of the RPS19 gene in 123 DBA patients identified 31 mutated subjects, whereas 92 seemed normal. 9 Informed consent was obtained from all patients included in the study. Our PCR primers also allow interrogation of six SNPs distributed along the gene The two parts of each probe hybridize to adjacent target sequences and are ligated by a thermostable ligase. A universal primer pair is used to amplify all ligated probes. The amplification product of each probe has a unique length ranging from 130bp to 400bp. Fragments are separated on an ABI Prism 3100-Avant automatic sequencer by using POP4 polymer and GS-ROX-500 molecular marker (Applera, Foster City, CA, USA), and analyzed with the Genescan software ver.3.1. Relative amounts of probe amplification products, as compared to control DNA sample, reflect the relative copy number of target sequences. (B) MLPA chromatogram of patient 2 carrying a whole gene deletion and a control subject (n-ctr). RPS19 peaks are labeled with their exon numbers. Unlabeled peaks represent genes in the 8p23 region and control genes (only the control probe 3544-L2910 is indicated). The values of peak sizes and area from patients and controls were used and normalized as follows: 1) the area of each peak (As) was divided by the sum of all 23 peak areas (∑As) of that sample; 2) for each peak this ratio (nAs=As/∑As) was divided by the relative peak area of the corresponding probe calculated as the average from (two or three) control DNA samples (nAc=Ac/∑Ac). A ratio (nAs/nAc) ranging from 0.8 to 1.2 was considered as a normal exon dosage; a deletion was suspected for ratio <0.7; a duplication was suspected for ratio >1. 
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These SNPs were used to divide the 92 non-mutated patients into two groups according to their haplotypes. Heterozygotes were 38/92 (41%). None displayed a loss of heterozygosity for one or more SNPs, suggesting the absence of intragenic deletions. Homozygotes were 54/92 (59%). It was assumed that some of them could carry a complete or partial deletion. MLPA was also used to look for duplication in both groups.
MLPA was performed on genomic DNA with the MLPA DBA test kit (MLPA KIT P212 DBA, MRCHolland, Amsterdam, The Netherlands) according to the manufacturer's instructions (http://www.mrc-holland.com). The probemix was composed of 23 probes: six probes mapped the RPS19 gene (one for each exon), one probe a region close to RPS19 (8.8 Kb upstream from the exon 1 probe), and ten the 8p23 region formerly suggested as a candidate for an unknown DBA gene. Six were control fragments. In each experiment, MLPA efficiency was tested by using a patient carrier of a known complete gene deletion of the RPS19 gene due to an unbalanced translocation (1;19) (p32; q13).
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MLPA revealed a significant reduction of the peak heights of all RPS19 exons in 3/54 homozygotes, suggesting the presence of heterozygous deletions of the entire RPS19 gene. A probe located 8.8 Kb centromeric to the RPS19 gene (DMRTC2) was also deleted in these 3 patients. All DNA samples showing evidence of a deletion were confirmed in a second MLPA experiment. Normal results in the other 89 patients showed the absence of intragenic deletions and duplications. No genomic rearrangement was discovered in the 8p23.3-8p22 region.
MLPA was also performed on the parents of each deleted patient; the absence of abnormalities in both parents proved that the three deletions were de novo.
To confirm these deletions, better define their extension and substantiate parental origin, we analyzed seventeen microsatellites spanning the 19q13 region from D19S47 to D19S178 (~2Mb centromeric and ~2Mb telomeric to the RPS19 gene). 11, 12 We also analyzed a microsatellite internal to ARHGEF1 gene using a forward fluorescently-labeled primer 5'-TAGTTGTGGGGT-CAGGATGG-3' and a reverse primer 5'-GAAGTTCCTC-CCCGACTTCT-3'.
We found that the extension of the deletions varied from ~0.06 to ~3Mb; the deletion was of maternal origin in patients 1 and 2, and paternal origin in patient 3 ( Figure   2 ). These patients (2 males, 1 female) displayed earlyonset anemia (age at diagnosis 0-4 months) and malformations: cranio-facial dysmorphisms, strabismus and urogenital malformations (patient 1), growth retardation (patient 2), and cardiac malformations (patient 3). Patient 1 was also mentally retarded. Initial steroid response was reported in patients 1 and 3; patient 3 died of sepsis during the first steroid course. Patient 2 was steroid unresponsive and therefore transfusion dependent.
Like other authors, we found MLPA efficient and rapid for analysis of gene dosage alterations. 8 In this study, it identified three unsuspected heterozygous RPS19 gene deletions missed by standard mutation screening PCRbased methods. Mutation screening of the RPS19 gene with a combination of sequencing and MLPA reached an overall rate of 28% (34/123). This was equivalent to a 3% increase in the detection rate compared to sequencing alone. Furthermore, whereas the frequency of genomic deletions in DBA patients was previously at 6% of RPS19 alterations, 7 this rises to 8.5% on the strength of our results. In our cohort, genomic deletions represent up to 12% of all mutations detected.
In conclusion, we stress that a gene-dosage technique, such as MLPA or FISH, should complement sequencing in a clinical environment since only a combined approach of this kind permits comprehensive detection of all mutations within the RPS19 gene. We strongly suggest that it should be applied as a complement to RPS19 sequencing to all subjects with a DBA phenotype. Paola Quarello, 1 Emanuela Garelli, 1 Alfredo Brusco,
